2013 China Outlook: Year Of The Snake To Bring Twists And Turns For Pharma
This article was originally published in PharmAsia News
Executive Summary
A sharp expansion in China’s Essential Drug List along with the National Drug Reimbursement List are among the twists and turns expected as the Year of the Snake is ushered in this February.
You may also be interested in...
China's New Guideline For Drug Pricing Favors Innovation And First-to-market Generics
SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.